Welcome to Vernalis Research
We develop and apply fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation.
Latest news
Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provides a general corporate update, as follows:
“As the business environment has evolved in response to the pandemic, Ligand has remained sharp with our operations and our partners […]
Success Milestone in Oncology Collaboration with Servier
Vernalis Research and Servier, an independent international pharmaceutical company, are pleased to announce the achievement of a milestone in their most recent oncology drug discovery collaboration on an undisclosed target.
This achievement is within the research […]
Interview in Drug Target Review with James Murray, Research Director at Vernalis
Read this Drug Target Review article discussing our innovative approach to drug discovery, and how we sustain symbiotic collaborations to progress our research.
Our approach
Our established group of experienced scientists is based at our fully-equipped research laboratories in Cambridge, UK.
We integrate fragment-based approaches, structural biology, biophysics, assay technology and molecular modelling with extensive synthetic organic and medicinal chemistry expertise to enable drug discovery on both established and novel targets.
We have the experience and capabilities for progressing projects from concept to clinic. We have generated lead compounds on enzymes, protein-protein interactions and GPCRs, leading to pre-clinical candidates for Chk1, Hsp90, Bcl-2, Mcl-1, FAAH and A2A.
Our business model
We balance an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical and biotechnology companies, and academic partners. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success. Recently disclosed collaborations include those with Servier, Daiichi Sankyo, Lundbeck, PhoreMost and Asahi Kasei Pharma, and we seek additional partnerships.
We also have an extensive portfolio of partnered and unpartnered drug candidates in pre-clinical and clinical development. To find out more, please contact us.
